Unknown

Dataset Information

0

PPARγ agonists promote the resolution of myelofibrosis in preclinical models.

ABSTRACT: Myelofibrosis (MF) is a non-BCR-ABL myeloproliferative neoplasm associated with poor outcomes. Current treatment has little effect on the natural history of the disease. MF results from complex interactions between (a) the malignant clone, (b) an inflammatory context, and (c) remodeling of the bone marrow (BM) microenvironment. Each of these points is a potential target of PPARγ activation. Here, we demonstrated the therapeutic potential of PPARγ agonists in resolving MF in 3 mouse models. We showed that PPARγ agonists reduce myeloproliferation, modulate inflammation, and protect the BM stroma in vitro and ex vivo. Activation of PPARγ constitutes a relevant therapeutic target in MF, and our data support the possibility of using PPARγ agonists in clinical practice.

SUBMITTER: Lambert J 

PROVIDER: S-EPMC8159700 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Myelofibrosis (MF) is a non-BCR-ABL myeloproliferative neoplasm associated with poor outcomes. Current treatment has little effect on the natural history of the disease. MF results from complex interactions between (a) the malignant clone, (b) an inflammatory context, and (c) remodeling of the bone marrow (BM) microenvironment. Each of these points is a potential target of PPARγ activation. Here, we demonstrated the therapeutic potential of PPARγ agonists in resolving MF in 3 mouse models. We sh  ...[more]

Similar Datasets

Genomics PPAR-y agonists promote the resolution of myelofibrosis in preclinical models
2021-04-16 | GSE141378 | GEO
Genomics PPAR-y agonists promote the resolution of myelofibrosis in preclinical models
| PRJNA593237 | ENA
Unknown Cannabidiol ameliorates mitochondrial disease via PPARγ activation in preclinical models.
| S-EPMC11375224 | biostudies-literature
Unknown PPARγ agonists promote differentiation of cancer stem cells by restraining YAP transcriptional activity.
| S-EPMC5308629 | biostudies-literature
Transcriptomics Androgen receptor agonists increase muscle mass and function in preclinical models of DMD
2017-05-12 | GSE98473 | GEO
Unknown Therapeutic Potential of TAAR1 Agonists in Schizophrenia: Evidence from Preclinical Models and Clinical Studies.
| S-EPMC8704992 | biostudies-literature
Unknown MFN2 agonists reverse mitochondrial defects in preclinical models of Charcot-Marie-Tooth disease type 2A.
| S-EPMC6109362 | biostudies-literature
Unknown PPARγ agonists delay age-associated metabolic disease and extend longevity.
| S-EPMC7681041 | biostudies-literature
Transcriptomics Amorfrutins are selective PPARγ agonists with potent antidiabetic properties
2012-05-02 | GSE28384 | GEO
Unknown Resolution phase lipid mediators of inflammation: agonists of resolution.
| S-EPMC3732499 | biostudies-literature